These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 36228758)

  • 81. An evidence based review of proton beam therapy: the report of ASTRO's emerging technology committee.
    Allen AM; Pawlicki T; Dong L; Fourkal E; Buyyounouski M; Cengel K; Plastaras J; Bucci MK; Yock TI; Bonilla L; Price R; Harris EE; Konski AA
    Radiother Oncol; 2012 Apr; 103(1):8-11. PubMed ID: 22405807
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Building consensus: development of a Best Practice Guideline (BPG) for surgical site infection (SSI) prevention in high-risk pediatric spine surgery.
    Vitale MG; Riedel MD; Glotzbecker MP; Matsumoto H; Roye DP; Akbarnia BA; Anderson RC; Brockmeyer DL; Emans JB; Erickson M; Flynn JM; Lenke LG; Lewis SJ; Luhmann SJ; McLeod LM; Newton PO; Nyquist AC; Richards BS; Shah SA; Skaggs DL; Smith JT; Sponseller PD; Sucato DJ; Zeller RD; Saiman L
    J Pediatr Orthop; 2013; 33(5):471-8. PubMed ID: 23752142
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Eastern Canadian Gastrointestinal Cancer Consensus Conference 2023.
    Al-Mansor E; Mahoney M; Chenard-Poirier M; Ramjeesingh R; Nair V; Kennedy E; Locke G; Welch S; Berry S; Couture F; Elimova E; Pollett A; Mahmud A; Wilson B; Armstrong D; Falkson C; Asmis T; Vickers M; Goodwin R
    Curr Oncol; 2023 Sep; 30(9):8172-8185. PubMed ID: 37754508
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Variations in Proton Therapy Coverage in the State of Texas: Defining Medical Necessity for a Safe and Effective Treatment.
    Thaker NG; Agarwal A; Palmer M; Hontiveros R; Hahn SM; Minsky BD; Walters R; Bingham J; Feeley TW; Buchholz TA; Frank SJ
    Int J Part Ther; 2016 Mar; 2(4):499-508. PubMed ID: 31772962
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Regulating for-profit virtual care in Canada: Implications for medical profession regulators and policy-makers.
    Adams TL; Leslie K
    Healthc Manage Forum; 2023 Mar; 36(2):113-118. PubMed ID: 36421019
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Impact of Oncology Drug Review Times on Public Funding Recommendations.
    Hussain M; Wong C; Taguedong E; Verma S; Mahsin M; Karim S; Lee-Ying R; Ezeife DA
    Curr Oncol; 2023 Aug; 30(8):7706-7712. PubMed ID: 37623039
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Inter-institutional data-driven education research: consensus values, principles, and recommendations to guide the ethical sharing of administrative education data in the Canadian medical education research context.
    Grierson L; Cavanagh A; Youssef A; Lee-Krueger R; McNeill K; Button B; Kulasegaram K
    Can Med Educ J; 2023 Nov; 14(5):113-120. PubMed ID: 38045068
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Should Canada adopt managed access agreements in Canada for expensive drugs?
    McPhail M; Bubela T
    J Law Biosci; 2023; 10(1):lsad014. PubMed ID: 37334249
    [TBL] [Abstract][Full Text] [Related]  

  • 89. RAPID framework for improved access to precision oncology for lethal disease: Results from a modified multi-round delphi study.
    Bright K; Mills A; Bradford JP; Stewart DJ
    Front Health Serv; 2023; 3():1015621. PubMed ID: 36926496
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Proton Therapy in Canada: Toward Universal Access and Health Equity With a Publicly Funded Facility.
    Safavi AH; Freeman C; Cheng S; Patel S; Mitera G; Kundapur V; Rutledge R; Tsang DS
    Int J Radiat Oncol Biol Phys; 2023 Jun; 116(2):394-403. PubMed ID: 36565727
    [No Abstract]   [Full Text] [Related]  

  • 91. Specific, Fair and Transparent: A Canadian Process for Funding Drugs for Rare Diseases.
    Stevenson H
    Healthc Pap; 2023 Jan; 21(1):28-33. PubMed ID: 36692913
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Recommendations for the safe use and handling of oral anticancer drugs in community pharmacy: A pan-Canadian consensus guideline.
    Vu K; Emberley P; Brown E; Abbott R; Bates JJ; Bourrier V; Djordjevic K; Greenall J; Leung M; Pasetka M; Paquet L; Logan H
    Can Pharm J (Ott); 2018; 151(4):240-253. PubMed ID: 30237839
    [No Abstract]   [Full Text] [Related]  

  • 93. The pan-Canadian Oncology Symptom Triage and Remote Support (COSTaRS)-Practice guides for symptom management in adults with cancer.
    Stacey D; Carley M
    Can Oncol Nurs J; 2017; 27(1):92-98. PubMed ID: 31148756
    [No Abstract]   [Full Text] [Related]  

  • 94. Proton Therapy Mediates Dose Reductions to Brain Structures Associated With Cognition in Children With Medulloblastoma.
    Sienna J; Kahalley LS; Mabbott D; Grosshans D; Santiago AT; Paulino ADC; Merchant TE; Manzar GS; Dama H; Hodgson DC; Chintagumpala M; Okcu MF; Whitehead WE; Laperriere N; Ramaswamy V; Bartels U; Tabori U; Bennett JM; Das A; Craig T; Tsang DS
    Int J Radiat Oncol Biol Phys; 2024 May; 119(1):200-207. PubMed ID: 38040059
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Canadian Contraception Consensus (Part 2 of 4).
    Black A; Guilbert E; ; Costescu D; Dunn S; Fisher W; Kives S; Mirosh M; Norman WV; Pymar H; Reid R; Roy G; Varto H; Waddington A; Wagner MS; Whelan AM; ; Ferguson C; Fortin C; Kielly M; Mansouri S; Todd N
    J Obstet Gynaecol Can; 2015 Nov; 37(11):1033-9. PubMed ID: 26629725
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Recommendations for the referral of patients for proton-beam therapy, an Alberta Health Services report: a model for Canada?
    Patel S; Kostaras X; Parliament M; Olivotto IA; Nordal R; Aronyk K; Hagen N
    Curr Oncol; 2014 Oct; 21(5):251-62. PubMed ID: 25302033
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Canadian Contraception Consensus (Part 1 of 4).
    Black A; Guilbert E; ; Costescu D; Dunn S; Fisher W; Kives S; Mirosh M; Norman WV; Pymar H; Reid R; Roy G; Varto H; Waddington A; Wagner MS; Whelan AM; ; Ferguson C; Fortin C; Kielly M; Mansouri S; Todd N;
    J Obstet Gynaecol Can; 2015 Oct; 37(10):936-42. PubMed ID: 26606712
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Guidelines for conducting pharmaceutical budget impact analyses for submission to public drug plans in Canada.
    Marshall DA; Douglas PR; Drummond MF; Torrance GW; Macleod S; Manti O; Cheruvu L; Corvari R
    Pharmacoeconomics; 2008; 26(6):477-95. PubMed ID: 18489199
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Pan-Canadian consensus recommendations for proton beam therapy access in Canada.
    Mitera G; Tsang D; McCurdy B; Goddard K; Ebacher A; Craig T; Greenland J; Kentish S; Koul R; Logie N; Morneau M; Morrison A; Pan L; Pantarotto J; Foxcroft S; Sussman J; Thompson R; Tyldesley S; Wright P; Hicks S; Brown E; Patel S;
    Radiother Oncol; 2022 Nov; 176():228-233. PubMed ID: 36228758
    [TBL] [Abstract][Full Text] [Related]  

  • 100.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.